- Pfizer (PFE) is proceeding with plans to commercialize an over-the-counter version of its blockbuster cholesterol-lowering drug Lipitor.
- The decision is controversial because some health experts believe that the drug should only be dispensed under a doctor's care due to the risk and to the difficulty for the general public of understanding how people's health is assessed.
- A 1200-person trial is underway to determine if the lower dose of Lipitor reduces patients' cholesterol vs generics available by prescription and if patients follow through on getting their blood tested. The trial should conclude by the year-end.
- The FDA has already rejected Merck's (MRK) plans to do the same with Mevacor.
- Pfizer believes that it will be successful by virtue of "new and creative" ways to convey product instructions to patients.
From other sites
at CNBC.com (Apr 10, 2015)
at Zacks.com (Apr 8, 2015)
at Zacks.com (Apr 7, 2015)
at Investopedia (Apr 7, 2015)
at MarketRealist.com (Mar 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs